Capital Markets: Recent Follow-on Offerings

Since 2009, we have been involved in 450+ public offerings including some of the nation's most notable securities transactions. Following are some recent representative offerings.

Completed Follow-on Offerings

  • Underwriters in Reata Pharmaceuticals $115.9 million Follow-On (July 2017)
  • Regulus Therapeutics $46.0 million Follow-On (July 2017)
  • Apollo Endosurgery $31.3 million Follow-On (July 2017)
  • Inovio Pharmaceuticals $75.0 million Follow-On (July 2017)
  • CymaBay Therapeutics $97.2 million Follow-On (July 2017)
  • Alder Biopharmaceuticals $172.5 million Follow-On (July 2017)
  • Arena Pharmaceuticals $150.0 million Follow-On (July 2017)
  • Underwriters in Egalet Corporation $30.0 million Follow-On (July 2017)
  • Minerva Neurosciences $41.8 million Follow-On (June 2017)
  • AveXis $287.5 million Follow-On (June 2017)
  • Underwriters in Pacific Biosciences of California $47.8 million Follow-On (June 2017)
  • Underwriters in Savara $42.9 million Follow-On (June 2017)
  • Senseonics $41.0 million Follow-On (May 2017)
  • GlycoMimetics $92.6 million Follow-On (May 2017)
  • Syndax Pharmaceuticals $49.7 million Follow-On (May 2017)
  • Underwriters in MINDBODY $141.4 million Follow-On (May 2017)
  • ZioPharm Oncology in its $50.0 million Follow-On (May 2017)
  • Underwriters in Arbor Realty Trust $77.9 million Follow-On (May 2017)
  • Underwriters in Accelerate Diagnostics $79.4 million Follow-On (May 2017)
  • Cytokinetics in its $75.0 million Follow-On (May 2017)
  • Underwriters in Ignyta $88.4 million Follow-On (May 2017)
  • Underwriters in AGNC Investment Corp. $507.2 million Follow-On (May 2017)
  • Underwriters in TransEnterix $24.9 million Follow-On (April 2017)
  • Underwriters in Karyopharm Therapeutics $40.0 million Follow-On (April 2017)
  • Underwriters in Audentes Therapeutics $86.3 million Follow-On (April 2017)
  • Arena Pharmaceuticals $79.4 million Follow-On (April 2017)
  • Underwriters in Wave Life Sciences $100.0 million Follow-On (April 2017)
  • Axovant $143.7 million Follow-On (April 2017)
  • FibroGen $120.0 million Follow-On (April 2017)
  • Everbridge $73.8 million Follow-On (April 2017)
  • Cara Therapeutics $92.1 million Follow-On (March 2017)
  • Underwriters in CytoSorbents $9.99 million Follow-On (March 2017)
  • Biocept $9.3 million Follow-On (March 2017)
  • Underwriters in Vital Therapies, Inc. $40.3 million Follow-On (March 2017)
  • Underwriters in Heat Biologics Inc.$4.0 million Follow-On (March 2017)
  • Bellicum Pharmaceuticals, Inc. in its $69.0 million Follow-On (March 2017)
  • Calithera Biosciences, Inc. in its $80.5 million Follow-On (March 2017)
  • Underwriters in Intrepid Potash, Inc. $60.4 million Follow-On (March 2017)
  • Underwriters in Anthera Pharmaceuticals, Inc. $15.0 million Follow-On (March 2017)
  • Aurinia Pharmaceuticals Inc. in its $173.1 million Follow-On (March 2017)
  • Underwriters in Ooma, Inc. $29.1 million Follow-On (March 2017)
  • Kite Pharma, Inc. in its $409.7 million Follow-On (March 2017)
  • Underwriters in Dermira, Inc. $193.8 million Follow-On (March 2017)
  • Underwriters in Global Blood Therapeutics $143.8 million Follow-On (February 2017)
  • Helius Medical Technologies in its $9.5 million Follow-On (February 2017)
  • Underwriters in Sierra Oncology $29.5 million Follow-On (February 2017)
  • CymaBay Therapeutics, Inc. in its $10.0 million Follow-On (February 2017)
  • Rigel Pharmaceuticals, Inc. in its $46.0 million Follow-On (January 2017)
  • Mirati Therapeutics, Inc. in its $68.7 million Follow-On (January 2017)
  • Arena Pharmaceuticals Inc. in its $50.0 million Follow-On (January 2017)
  • Aurinia Pharmaceuticals Inc. in its $28.8 million Follow-On (December 2016)
  • Clearside Biomedical, Inc. in its $41.4 million Follow-On (December 2016)
  • Xencor in its $126.5 million Follow-On (November 2016)
  • TRACON Pharmaceuticals, Inc. in its $17.4 million Follow-On (November 2016)
  • Aclaris Therapeutics, Inc. in its $91.0 million Follow-On (November 2016)
  • AmpliPhi Biosciences Corporation in its $4.0 million Follow-On (November 2016)
  • Underwriters in Invitae Corporation $43.9 million Follow-On (November 2016)
  • Flexion Therapeutics in its $64.8 million Follow-On (November 2016)
  • Underwriters in HealthEquity, Inc. $89.6 million Follow-On (October 2016)
  • Sunesis Pharmaceuticals, Inc. $19.0 million Follow-On (October 2016)
  • Underwriters in Ascendis Pharma Inc. $136.4 million Follow-On (October 2016)
  • Underwriters in Nektar Therapeutics in $201.8 million Follow-On (October 2016)
  • Biocept Inc. in its $10.0 million Follow-On (October 2016)
  • Cidara Therapeutics, Inc. in its $25.0 million Follow-On (October 2016)
  • Versartis, Inc. in its $63.4 million Follow-On (September 2016)
  • Enphase Energy, Inc. in its $15.6 million Follow-On (September 2016)
  • Aquinox Pharmaceuticals Inc. in its $65.5 million Follow-On (September 2016)
  • Immune Design Corp. in its $32.7 million Follow-On (September 2016)
  • Underwriters in Xenon Pharmaceuticals Inc. $30.0 million Follow-On (September 2016)
  • AveXis Inc. in its $168.8 million Follow-On (September 2016)
  • Sophiris Bio in its $29.9 million Follow-On (August 2016)
  • Eiger BioPharmaceuticals in its $20 million Follow-On (August 2016)
  • Underwriters in Recro Pharma $14.9 million Follow-On (August 2016)
  • Immunocellular Therapeutics in its $7.5 million Follow-On (August 2016)
  • Acadia Pharmaceuticals Inc. in its $200.0 million Follow-On (August 2016)
  • BioMarin Pharmaceutical Inc. in its $720.0 million Follow-On (August 2016)
  • Paratek Pharmaceuticals, Inc. in its $55.3 million Follow-On (June 2016)
  • Scynexis Inc. in its $22.5 million Follow-On (June 2016)
  • GlycoMimetics, Inc. in its $20.1 million Follow-On (June 2016)
  • Minerva Neurosciences, Inc. in its $57.5 million Follow-On (June 2016)
  • Underwriters in Dermira Inc. $144.9 million Follow-On (June 2016)
  • Flexion Therapeutics, Inc. in its $77.0 million Follow-On (June 2016)
  • AmpliPhi Biosciences Corporation in its $5.0 million Follow-On (May 2016)
  • Sophiris Bio, Inc. in its $5.0 million Follow-On (May 2016)
  • Biocept Inc. in its $5.0 million Follow-On (April 2016) 
  • Underwriters in Ignyta, Inc. $57.5 million Follow-On (April 2016)
  • Underwriters in Durect Corporation $17.2 million Follow-On (April 2016)
  • Alder Biopharmaceuticals, Inc. in its $143.8 million Follow-On (April 2016)
  • Underwriters in Vitae Pharmaceuticals, Inc. $40.0 million Follow-On (March 2016)
  • Underwriters in Energy Fuels Inc. $12.1 million Follow-On (March 2016)
  • Adamas Pharmaceuticals in its $61.8 million Follow-On (January 2016)
  • Underwriters in Prothena Corporation plc $119.3 million Follow-On (January 2016)
  • Underwriters in Epizyme, Inc. $138.0 million Follow-On (January 2016)
  • Underwriters in Otonomy, Inc. $115.0 million Follow-On (January 2016)
  • Acadia Pharmaceuticals in its $300.0 million Follow-On (January 2016)
Related Practices & Industries

Capital Markets